NFE2L2 and renal carcinoma: Next, we examined the efficacy of NRF2 siRNA delivery in PDT sensitization of 4 additional types of cancer cells: human breast carcinoma cell line MCF7, colon carcinoma cell line HCT116, renal carcinoma cell line A498, and glioblastoma cell line A172.